Table of Contents
Two Italian ITP Studies 1. Borderline thrombocytopenia 2. Rituximab
PPT Slide
PPT Slide
PPT Slide
PPT Slide
PPT Slide
PPT Slide
How to become an expert in ITP
Research in Italy: The GIMEMA Group
PPT Slide
Background
National Health and Nutrition Examination Survey III
Objective of the study
Study design and setting
Patients
Methods
Age and sex distribution of 260 cases entering 6 mo observation
Platelet distribution of 260 cases entering 6 mo observation
Summary of the results
PPT Slide
PPT Slide
PPT Slide
Conclusions
PPT Slide
Rituximab Therapy for ITP
Phase I-II trials: Patients’ characteristics*
Phase I-II trials: Results
PPT Slide
Response Duration vs. Type of Response
Patient characteristics based on response to treatment
Duration of ITP and Response
Adverse events
Re-treatment in Relapsed CR/PR Patients
B-cell counts
B-cell Counts: CR vs PR
Median Anti-Platelet-Antibody Titers
Long Term Follow-Up of Patients with Immune Thrombocytopenic Purpura (ITP) Whose Initial Response to Rituximab Lasted a Minimum of 1 Year
Long Term Follow-Up of Patients with Immune Thrombocytopenic Purpura (ITP) Whose Initial Response to Rituximab Lasted a Minimum of 1 Year
Rituximab for adult ITP: Conclusions
|